ArticleDiscover oncology2025
A new prognostic model for lung adenocarcinoma according propionate metabolism related genes: a comprehensive bioinformatic study.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe prognostic mechanisms of lung adenocarcinoma (LUAD) remain unclear, while the propionate metabolic pathway has been implicated in promoting tumor growth across multiple cancer types. This study aims to elucidate the mechanistic basis by which the propionate pathway influences LUAD progression at the genetic level.
methodsThe TCGA-LUAD cohort was retrieved from The Cancer Genome Atlas (TCGA), and LUAD-related datasets (GSE13213, GSE72079) were obtained from the Gene Expression Omnibus (GEO). Differentially expressed genes (DEGs) between LUAD and normal tissues were first identified, followed by intersection with propionate metabolism-related genes (PMRGs) to derive DE-PMRGs. After partitioning these genes into training and validation sets, a prognostic risk model was constructed via univariate Cox regression and LASSO regression analysis, which was validated in independent cohorts. Patients were stratified into high- and low-risk groups based on the risk model, followed by gene set variation analysis (GSVA), immune microenvironment profiling, and chemosensitivity prediction.
resultsA total of 166 DE-PMRGs were identified by intersecting 4,403 DEGs with 531 PMRGs. A risk model was constructed using five characteristic genes (LDHA, KYNU, SLC2A1, CFTR, MAOB) via univariate Cox and LASSO analyses. GSVA revealed 18 activated pathways in the high-risk group (e.g., heme metabolism, P53 signaling), versus 14 pathways in the low-risk group (e.g., E2F targets, mTORC1 signaling). Significant differences were observed in 14 immune cell types (e.g., eosinophils, neutrophils) and 4 immune checkpoints (PDCD1LG2, CD274, CD27, IDO1) between risk groups. LDHA, KYNU, and SLC2A1 were significantly positively correlated with activated CD4 + T cells, γδ T cells, and memory B cells, while CFTR and MAOB were associated with 9 immune cell types (e.g., activated B cells, eosinophils). Eight chemotherapeutic agents were identified to correlate with risk scores via drug sensitivity analysis.
conclusionThis study identifies five propionate metabolism-related genes (LDHA, KYNU, SLC2A1, CFTR, MAOB) that may influence LUAD prognosis, providing a scientific foundation for further mechanistic investigations and potential clinical applications. (Liu C, He L, Peng Z, Luo J, A New Prognostic Model for Lung Adenocarcinoma According Propionate Metabolism Related Genes: A Comprehensive Bioinformatic Study, Abstract Book of MEDLIFE2024 & ICBLS2024 (ISBN:979-8-88599-099-8), 2024.).
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.